



Evaluation of the Effectiveness of Common Hospital Hand Disinfectants Against Methicillin-Resistant Staphylococcus aureus, Glycopeptide-Intermediate S. aureus, and Heterogeneous Glycopeptide-Intermediate S. aureus •

Author(s): Mandy Wootton, PhD; Timothy R. Walsh, PhD; Eleri M. Davies, MRCPath;

Robin A. Howe, MRCPath

Source: Infection Control and Hospital Epidemiology, Vol. 30, No. 3 (March 2009), pp. 226-232 Published by: The University of Chicago Press on behalf of The Society for Healthcare Epidemiology of America

Stable URL: http://www.jstor.org/stable/10.1086/595691

Accessed: 21/02/2014 08:58

Your use of the JSTOR archive indicates your acceptance of the Terms & Conditions of Use, available at http://www.jstor.org/page/info/about/policies/terms.jsp

JSTOR is a not-for-profit service that helps scholars, researchers, and students discover, use, and build upon a wide range of content in a trusted digital archive. We use information technology and tools to increase productivity and facilitate new forms of scholarship. For more information about JSTOR, please contact support@jstor.org.



The University of Chicago Press and The Society for Healthcare Epidemiology of America are collaborating with JSTOR to digitize, preserve and extend access to Infection Control and Hospital Epidemiology.

http://www.jstor.org

ORIGINAL ARTICLE

Evaluation of the Effectiveness of Common Hospital Hand Disinfectants Against Methicillin-Resistant *Staphylococcus aureus*, Glycopeptide-Intermediate *S. aureus*, and Heterogeneous Glycopeptide-Intermediate *S. aureus*

Mandy Wootton, PhD; Timothy R. Walsh, PhD; Eleri M. Davies, MRCPath; Robin A. Howe, MRCPath

BACKGROUND. The presence of methicillin-resistant *Staphylococcus aureus* (MRSA) and glycopeptide-intermediate *S. aureus* (GISA) in hospitals poses a significant challenge to hospital infection control teams. The use of disinfectants for both surface and hand cleaning is an essential part of the infection control measures.

OBJECTIVE. To evaluate the effectiveness of common hospital hand disinfectants against MRSA, GISA, and heterogeneous GISA (hGISA).

METHODS. For methicillin-susceptible *S. aureus* (MSSA), MRSA, GISA, and hGISA, the levels of susceptibility to hand disinfectants and their active ingredients were determined. Suspension tests were performed on commercial handwashing products.

RESULTS. Minimum inhibitory concentrations (MICs) of 2-propanol, chlorhexidine, and hexachlorophene were similar for all phenotypes. The MICs of cetrimide and triclosan were higher for the MRSA, GISA, and hGISA strains than for the MSSA strain. The MICs for the chlorhexidine-containing agents Hibisol and Hibiscrub (AstraZeneca) and for the propanol-containing agent Sterillium (Medline) were 1–2-fold lower for the MSSA strains than for the MRSA, GISA, and hGISA strains. Suspension tests showed that the GISA and hGISA strains were less susceptible to the triclosan-containing agent Aquasept (SSL) than were the MRSA and MSSA strains, with resistance increasing with glycopeptide resistance. Products containing Betadine (Purdue) were more effective against the GISA and hGISA strains than against the MRSA and MSSA strains, especially after the strain was exposed to the product for 30 seconds.

CONCLUSIONS. Using the EN 1040 standard criteria for the performance of disinfectants, we determined that all agents, except 50% Aquasept for hGISA and 0.33% hexachlorophene for GISA, performed effectively. However, the GISA and hGISA strains were less susceptible to triclosan-containing products, compared with the MRSA stains, but were more susceptible to products containing Betadine.

Infect Control Hosp Epidemiol 2009; 30:226-232

Staphylococcus aureus—in particular, methicillin-resistant *S. aureus* (MRSA)—is a major cause of hospital-acquired infection. Strains of methicillin-susceptible *S. aureus* (MSSA) are generally susceptible to commonly used hospital disinfectants; however, some MRSA strains have been reported to have reduced susceptibility to chlorhexidine, quaternary ammonium compounds (QACs), cetrimide, and benzalkonium chloride.¹⁻⁴ For MRSA, a number of genes (*qacA–D* and *norA*), some carried by plasmids, have been shown to be resistant to chlorhexidine, diamidines, and QACs.⁵⁻⁸ The presence of *qac* genes is common among MRSA strains and coagulase-negative staphylococci; these genes mediate the efflux-based resistance to QACs.⁹ These genes have also been found in a strain of vancomycin-resistant *S. aureus* isolated in the United States.¹⁰ Further reports have shown a ge-

netic linkage between these genes and the antibiotic resistance genes *blaZ*, *aacA–aphD*, *dfrA*, and *ble* on the same plasmids, and concern about the transfer of these genes is understandable.¹¹⁻¹³

Alternatively, intrinsic resistance to biocides can be conferred by cell-wall thickness and by characteristics associated with biofilm production, such as slow growth rate and altered cell-wall composition.¹⁴ Reduced cellular permeability and components of the cell wall may limit the concentration of active biocides that reach the target site(s).¹⁵ For *Bacillus megaterium*, a thickened and altered peptidoglycan component of the cell walls has demonstrated reduced susceptibility to disinfectants and antiseptics.¹⁶ The cell walls of staphylococci are composed of peptidoglycan and teichoic acid and are not normally an effective barrier against disinfectants or antisep-

From NPHS Microbiology Cardiff, University Hospital Wales (M.W., E.M.D., R.A.H.), and the Department of Medical Microbiology, Cardiff University (T.R.W.), Heath Park, Cardiff, United Kingdom.

Received July 9, 2008; accepted October 4, 2008; electronically published January 26, 2009.

^{© 2009} by The Society for Healthcare Epidemiology of America. All rights reserved. 0899-823X/2009/3003-0004\$15.00. DOI: 10.1086/595691

TABLE 1. Mean Minimum Inhibitory Concentrations (MICs; mg/L) of Agents Used in Hand Disinfectants, With Levels of Susceptibility of 6 Phenotypes of Staphylococcus aureus

Phenotype, MIC	1-propanol	2-propanol	Chlorhexidine	Triclosan	Cetrimide	Hexachlorophene	
MSSA (n = 10)						_	
MIC range	128	32	0.008-0.015	.008-0.015 0.015-2		0.25-0.5	
MIC_{50}	128	32	0.008	0.015	2	0.5	
MIC_{90}	128	32	0.015	0.5	2	0.5	
EMRSA-15 ($n = 10$)							
MIC range	128	32	0.015	0.015 - 0.03	8-16	0.25-0.5	
MIC_{50}	128	32	0.015	0.03	8	0.5	
MIC_{90}	128	32	0.015	0.03	8	0.5	
EMRSA-16 ($n = 10$)							
MIC range	128	32	0.015	0.015	2-32	0.25-1	
MIC_{50}	128	32	0.015	0.015	16	0.5	
MIC_{90}	128	32	0.015	0.015	16	0.5	
MRSA (n = 16)							
MIC range	64-128	32-64	0.008 - 0.06	0.015-4	2-16	0.25-1	
MIC_{50}	128	32	0.015	0.03	8	0.5	
MIC_{90}	128	64	0.03	2	8	0.5	
hGISA (n = 45)							
MIC range	16-128	32-64	0.008-0.03	0.015-2	4-32	0.12-0.5	
MIC_{50}	32	32	0.03	1	16	0.25	
MIC_{90}	32	32	0.03	2	16	0.5	
GISA (n = 8)							
MIC range	16-32	32-64	0.008-0.03	0.015-4	2-16	0.25-0.5	
MIC_{50}	32	32	0.015	0.015	8	0.25	
MIC_{90}	32	64	0.015	2	16	0.5	

NOTE. The MIC₅₀ and MIC₉₀ values are the MICs required to inhibit 50% and 90% of the organisms, respectively. EMRSA-15, epidemic strain of type 15 methicillin-resistant *S. aureus* (MRSA); EMRSA-16, epidemic strain of type 16 MRSA; GISA, glycopeptide-intermediate *S. aureus*; hGISA, heterogeneous GISA; MSSA, methicillin-susceptible *S. aureus*.

tics.¹⁷ For clinical strains of *S. aureus* with intermediate resistance to glycopeptide (hereafter referred to as glycopeptide-intermediate *S. aureus* [GISA]) or with heterogeneous GISA (hereafter referred to as hGISA), the cell wall is grossly thickened with altered cross-linking, and it is possible that these alterations in the cell wall may affect susceptibility to disinfectants.

The emergence of GISA strains and the more abundant hGISA strains is likely to pose a major challenge to hospital infection control teams; with enhanced infection control measures already in operation in many hospitals, the need for accurate data on the efficacy of disinfectant agents against these strains is paramount. A cornerstone of these infection control measures will be effective hand disinfection to prevent the spread of infection from patient to patient, either by healthcare workers or visiting persons. In our study, we evaluated the effectiveness of the cleaning agents used in hand disinfectants and of commercially available hand disinfection products against a range of S. aureus strains with differing levels of susceptibility to methicillin and glycopeptide. Minimum inhibitory concentrations (MICs) of cleaning agents were determined, and suspension tests were employed to mimic the use of hand disinfectants.

METHODS

MICs of Cleaning Agents

The MICs were determined for the following cleaning agents, by the use of the Clinical Laboratory Standards Institute recommended methods and Mueller-Hinton agar plates with log 2 dilutions (from 0.008 to 128 mg/L): povidone-iodine (a halogen-releasing agent), triclosan (a bisphenol compound), cetrimide (a QAC), hexachlorophene (a bisphenol compound), 1-propanol (an alcohol), 2-propanol (an alcohol), and chlorhexidine (a biguanidine derivative). Also tested were the following commercial hand disinfectant products, which were also placed in Mueller-Hinton agar with log 2 dilutions: Hibisol (2.5% chlorhexidine gluconate) and Hibiscrub (20% chlorhexidine gluconate) from AstraZeneca; Sterillium (45% 2-propanol, 30% 1-propanol, and 0.2% mecetronium etilsulphate) from Medline; Aquasept (2% triclosan, diluted to give a range of 0.0015%-0.08%) and Manusept (0.5% triclosan, diluted to give a range of 0.0006%-0.6%) from SSL; and Betadine skin cleanser (4% povidone-iodine), Betadine aqueous solution (10% povidone-iodine), and Betadine alcoholic solution (10% povidone-iodine in alcohol) from Purdue.18

TABLE 2. Mean Minimum Inhibitory Concentrations (MICs; mg/L) of Commercially Available Hand Disinfectants, With Levels of Susceptibility of 4 Phenotypes of Staphylococcus aureus

						Betadine		
Phenotype, MIC	Hibisol	Hibiscrub	Sterillium	Aquasept	Manusept	Skin cleanser	Aqueous solution	Alcoholic solution
MSSA (n = 10)								_
MIC range	0.03	0.0015	0.015-0.06	0.0012 to >0.6	0.0012 to >0.08	0.12 - 0.5	2.5	2.5
MIC_{50}	0.03	0.0015	0.015	0.0012	0.0025	0.5	2.5	2.5
MIC_{90}	0.03	0.0015	0.03	>0.6	>0.08	0.5	2.5	2.5
MRSA (n = 10)								
MIC range	0.03-0.06	0.003	0.03-0.25	0.0012	0.0012-0.005	0.03-0.5	2.5	2.5
MIC_{50}	0.06	0.003	0.12	0.0012	0.0025	0.06	2.5	2.5
MIC_{90}	0.06	0.003	0.12	0.0012	0.005	0.5	2.5	2.5
hGISA (n = 11)								
MIC range	0.03 - 0.12	0.0015-0.006	0.03-0.25	0.0012-0.3	0.0025 to >0.08	0.03-0.5	2.5-5	2.5
MIC_{50}	0.06	0.003	0.12	0.0012	0.0025	0.5	2.5	2.5
MIC_{90}	0.06	0.003	0.25	0.3	>0.08	0.5	2.5	2.5
GISA $(n = 10)$								
MIC range	0.03-0.06	0.0015-0.006	0.03-0.25	0.0012-0.3	0.0025 to >0.08	0.03-0.5	2.5	2.5
MIC_{50}	0.03	0.0015	0.12	0.0012	0.0025	0.5	2.5	2.5
MIC_{90}	0.06	0.003	0.25	0.3	0.08	0.5	2.5	2.5

NOTE. The MIC₅₀ and MIC₆₀ values are the MICs required to inhibit 50% and 90% of the organisms, respectively; the MICs of these commercially available hand disinfectants were placed on Mueller-Hinton agar plates with log 2 dilutions. GISA, glycopeptide-intermediate S. aureus; hGISA, heterogeneous GISA; MRSA, methicillin-resistant S. aureus; MSSA, methicillin-susceptible S. aureus.

The strains tested were 10 strains of MSSA, 10 epidemic strains of type 15 MRSA, 10 epidemic strains of type 16 MRSA, 16 strains of MRSA, 45 strains of hGISA, and 8 strains of GISA (plus the control S. aureus strain ATCC 6538). Two sets of related hGISA and GISA strains were included in the strain sets used: LIM1 (hGISA) and LIM2 and LIM3 (GISA); and PC1 (hGISA) and PC2 (GISA).

Suspension Tests

Suspension tests were performed with agent concentrations (ie, at 100% concentration and/or at 50% concentration but diluted with water) and recorded times (ie, for handwashing duration) in a way that mimicked the actual use of hand disinfectants. Suspension tests were performed, according to the Council of Europe and the European standard EN 1040, on the commercial agents Hibiscrub (used at 10%), Hibisol (used at 100% and 50%), Aquasept (used at 50%), Manusept (used at 50%), Sterillium (used at 100% and 50%), Betadine antiseptic solution (used at 100% and 50%), Betadine alcoholic solution (used at 100% and 50%), Betadine skin cleanser (used at 100% and 50%), and 0.33% hexachlorophene (used at a 10% concentration of the commercially available 3% soap).19,20

The disinfectants were inactivated during suspension tests by the use of one of the following neutralizing fluids:

1. 3 g lecithin (Sigma), 30 mL Tween 80 (Sigma), 5 g Na thiosulphate (BDH), 10 mL phosphate buffer, and 1 g l-histidine (Sigma) in 1 L of water (for Betadine alcoholic solution and Betadine skin cleanser).

- 2. 3 g lecithin, 30 mL Tween 80, 5 g Na thiosulphate, 10 mL phosphate buffer, and 30 g saponine (Sigma) in 1 L of water (for Aquasept, Manusept, and 0.33% hexachlorophene).
- 3. 30 mL Tween 80, 4 g sodium dodecyl sulfate, 3 g lecithin, and 10 mL phosphate buffer in 1 L of water (for Hibiscrub, Hibisol, and Sterillium).

Each disinfectant solution (ie, 8 mL) was mixed with 1 mL of water of standard hardness (prepared by adding 3 mL of a solution of 31.74 g magnesium chloride and 73.99 g calcium chloride in 1 L of water to 4 mL of a solution of 56.03 g sodium bicarbonate [BDH] in 1 L of water) and 1 mL of test bacterial suspension (approximately 1.5×10^8 organisms) (prepared by adding 0.5 McFarland suspension from culture plates to diluents of 1 g peptone [Sigma] or 8.5 g sodium chloride [BDH] in 1 L water) and incubated for 30, 60, 120, and 600 seconds at room temperature. Simultaneously, 1 mL of bacterial suspension was added to 9 mL of water of standard hardness and spread onto a tryptone soya agar plate for initial inoculum calculations. These samples were removed and added to 1 mL of water of standard hardness and 8 mL of neutralizing fluid to inactivate disinfectant activity. After 5 minutes at room temperature, 500 µL of the bacterial suspension samples were spread onto duplicate tryptone soya agar plates, and these plates were incubated in air at 37°C for 24 hours. The surviving bacteria were counted, and a cleaning agent was deemed to be effective against the organism tested if the reduction in the number of viable surviving colonies (ie, the log reduction factor) was at least 10⁵ colony-forming units/mL within 5 minutes, according to the criteria of European and British standards.

TABLE 3. Effectiveness of Commercial Handwashing Products Against 4 Phenotypes of Staphylococcus aureus, Based on Log Reduction Factors (LRFs)

LRF, by exposure time Agent, phenotype 30 sec 60 sec 120 sec 600 sec Betadine aqueous 100% MSSA 2 47 3 79 5.84 5.84 MRSA 5.82 2.1 3.46 5.82 hGISA 2.37 3.29 5.54 5.85 **GISA** 2.05 3.15 5.81 5.81 Betadine aqueous 50% MSSA 1.28 3.04 5.99 6.06 MRSA 0.61 2.23 5.6 5.75 hGISA 2.15 3.83 5.7 5.7 **GISA** 1.95 4.26 5.64 5.69 Betadine alcohol 100% 5.87 MSSA 5.45 5.85 5.87 MRSA 5.83 5.42 5.7 5.83 hGISA 5.79 5.84 5.84 5.84 **GISA** 5.08 5.75 5.75 5.75 Betadine alcohol 50% **MSSA** 1.74 1.92 5.89 5.89 MRSA 1.49 1.94 5.81 5.81 hGISA 2.71 3.56 5.67 5.91 **GISA** 1.47 1.82 4.64 5.78 Betadine skin cleanser 100% MSSA 1.92 3.47 5.81 5.84 MRSA 2.74 4.64 5.75 5.75 hGISA 3.38 4.95 5.46 5.46 GISA 3.27 4.62 5.51 5.51 Betadine skin cleanser 50% MSSA 1.55 2.21 5.9 5.9 **MRSA** 2.01 5.97 5.97 3.18 hGISA 1.57 2.67 5.66 5.86 **GISA** 1.15 2.31 5.75 5.91 Hibiscrub 10% 5.39 MSSA 5.88 5.91 5.91 **MRSA** 4 95 5 49 5.87 5.87 5.75 5.75 hGISA 5.05 5.71 5.98 5.99 5.99 GISA 4.91 Hibisol 100% MSSA 5.87 5.87 5.87 5.87 MRSA 5.85 5.85 5.85 5.85 hGISA 5.93 5.93 5.93 5.93 **GISA** 5.87 5.87 5.87 5.87 Hibisol 50% MSSA 5.99 6.02 6.02 6.02 MRSA 5.87 5.89 5.89 5.89 hGISA 5.91 5.91 5.91 5.91 5.78 5.84 5.84 5.84 GISA Aquasept 50% MSSA 3.95 4.14 5.34 5.88 MRSA 3.95 4.39 5.43 5.92 hGISA 2.68 3.19 3.61 4.47 **GISA** 3.7 3.96 4.95 5.87 Manusept 50% 5.91 MSSA 5.38 5.66 5.91

(continued)

(Continued) TABLE 3.

	LRF, by exposure time					
Agent, phenotype	30 sec	60 sec	120 sec	600 sec		
MRSA	5.27	5.86	5.86	5.86		
hGISA	4.57	5.05	5.26	5.47		
GISA	5.85	5.85	5.85	5.85		
Sterillium 100%						
MSSA	5.94	5.94	5.94	5.94		
MRSA	5.72	5.72	5.72	5.72		
hGISA	5.57	5.66	5.66	5.66		
GISA	5.51	5.51	5.51	5.51		
Sterillium 50%						
MSSA	4.33	5.49	5.86	5.95		
MRSA	4.9	5.79	5.97	5.97		
hGISA	4.95	5.96	5.97	5.97		
GISA	3.25	4.98	5.99	5.99		
Hexachlorophene 0.33%						
MSSA	2.28	2.46	4.46	5.92		
MRSA	1.71	2.19	3.82	5.33		
hGISA	2.13	2.69	3.75	5.53		
GISA	2.23	2.56	3.71	4.99		

NOTE. GISA, glycopeptide-intermediate S. aureus; hGISA, heterogeneous GISA; MRSA, methicillin-resistant S. aureus; MSSA, methicillin-susceptible

Colony counts at 30 seconds were used to mimic the actual time it takes to use a hand disinfectant. The recommendation by the Healthcare Infection Control Practices Advisory Committee for duration of hand washing is currently 15 seconds; however, a time of 30 seconds was selected as the minimum time tested efficiently in vitro.

RESULTS

MICs of Cleaning Agents

The MICs of the cleaning agents used in hand disinfectants are shown in Table 1. The MICs of 2-propanol, chlorhexidine, and hexachlorophene were similar for all phenotypes. In contrast, the MIC₅₀ and MIC₉₀ values of 1-propanol for GISA and hGISA were 2-fold lower than those for MRSA and MSSA, which suggests that GISA and hGISA are more susceptible to 1-propanol. In contrast, the susceptibility to the hand disinfectant Sterillium containing 45% 2-propanol, 30% 1-propanol, and 0.2% mecetronium etilsulphate was similar for MRSA, GISA, and hGISA but lower for MSSA.

For MRSA, GISA, and hGISA, the cetrimide and triclosan MIC₅₀ values were 2-4-fold higher than those for MSSA, and the cetrimide and triclosan MIC₉₀ values were 2-8-fold higher than those for MSSA. The levels of susceptibility to commercially available hand disinfectants were similar for all strains, regardless of the vancomycin resistance phenotype (Table 2). However, the MICs of the chlorhexidine-containing agents Hibisol and Hibiscrub and the propanol-containing Sterillium were 1–2-fold lower for MSSA than for MRSA, GISA, and hGISA.

TABLE 4. Mean Log Reduction Factors Used to Determine the Effectiveness of 9 Commercial Handwashing Products (After 30 Seconds of Exposure) Against 4 Phenotypes of Staphylococcus aureus

Phenotypes	Betadine aqueous	Betadine alcohol	Betadine skin	Hibiscrub	Hibisol	Aquasept	Manusept	Sterillium	Hexachlorophene
MSSA and MRSA	1.62	3.53	2.06	5.17	5.93	3.95	5.33	4.62	1.99
hGISA and GISA	2.13	3.77	2.35	4.98	5.85	3.19	5.21	4.1	2.18

GISA, glycopeptide-intermediate S. aureus; hGISA, heterogeneous GISA; MRSA, methicillin-resistant S. aureus; MSSA, methicillin-susceptible NOTE. S. aureus.

Suspension Tests


According to the EN 1040 standard criteria for the performance of disinfectants, all cleaning agents, except 50% Aquasept for hGISA and 0.33% hexachlorophene for GISA, were effective, with log reduction factors of 5 or more at 600 seconds (ie, at 10 minutes). With the use of Aquasept at 50% strength, the hGISA strains had a mean log reduction factor of 4.47 that was equivalent to a kill rate of 74.6% in 5 minutes. This suggests that hGISA strains are slightly more resistant to this agent than are the MRSA, MSSA, and GISA strains, with log reduction factors of 100%, 100%, and 100%, respectively. This correlates well with the higher MICs of triclosan found for hGISA (Tables 1 and 3). For GISA strains, the log reduction factor achieved with 0.33% hexachlorophene was 4.99, which suggests a slight lowering of susceptibility to this agent.

DISCUSSION

Concern has been steadily growing with regard to the potential coresistance to antibiotics and disinfectants of clini-

cally important bacteria. The dominance of MRSA and the emerging threat posed by GISA and hGISA in the clinical setting heighten the importance of hand disinfection as an infection control measure. The altered cell-wall physiology seen in strains of GISA and hGISA, and their increased resistance to glycopeptides, may be related to resistance to disinfectants; however, it is unlikely to be the sole factor.

In our study, the MICs of the hand disinfection agents 2propanol, chlorhexidine, and hexachlorophene were similar for all phenotypes, which indicates that there are no significant differences between the levels of susceptibility for the GISA, hGISA, MRSA, and MSSA strains. In contrast, the levels of susceptibility to cetrimide were lower for the MRSA, GISA, and hGISA strains than they were for the MSSA stains, which confirms previous reports of reduced susceptibility to QACs observed for MRSA, with MICs that were 1.5-3-fold higher, compared with those for MSSA.²¹ For MRSA strains, there is the possible presence of QAC resistance qac genes, and, for QAC-resistant biofilm-associated cells, slow growth rates were shown to be the predominant resistance factor.²²



Efficacy of Aquasept, Manusept, and Sterillium against related strains of Staphylococcus aureus with intermediate resistance to glycopeptide and with heterogeneous intermediate resistance to glycopeptide. For the bacterial suspension tests, the surviving bacteria were counted, and a cleaning agent was deemed to be effective against the organism tested if the reduction in the number of viable surviving colonies (ie, the log reduction factor) was 105 colony-forming units (cfu)/mL or more within 5 minutes, according to the criteria of European and British standards.

All GISA and hGISA strains exhibited slower growth rates, compared with the MRSA stains, and have been associated with contamination of biomedical devices, which suggests an ability to produce biofilms and therefore a tendency toward resistance to QACs.^{23,24} QACs are commonly used in skin disinfectant products, and, because GISA and hGISA strains show the same propensity for resistance as do MRSA strains, care should be taken whenever these compounds are used for effective skin disinfection.

Triclosan susceptibility was also reduced for MRSA, GISA, and hGISA, compared with MSSA, with MIC90 values of 2 mg/L and with some isolates having triclosan MICs of 2 and 4 mg/L. These data support previous reports of triclosanresistant strains of S. aureus, with triclosan MICs of 2-4 mg/ L and of 32 mg/L. 25,26 Triclosan-containing preparations, such as Aquasept, are regularly used in baths at concentrations of 4-5 mg/L to eradicate MRSA from carrier patients. However, in the case of resistant isolates having triclosan MICs of 32 mg/L, and also those with low-level resistance (ie, 4 mg/L), the triclosan concentration in the bath water would not be sufficient to eradicate the microbe.²⁶ In our study, no epidemic strains of type 16 MRSA exhibited elevated triclosan MICs, as found in previous reports and in contrast to a report in 2002 that showed triclosan resistance occurring in epidemic strains of type 16 MRSA.^{27,28} The reduced levels of susceptibility to the chlorhexidine-containing agents Hibisol and Hibiscrub found for MRSA, GISA, and hGISA, compared with those found for MSSA, confirm the association between methicillin resistance and chlorhexidine resistance.^{1,21}

Biocide concentrations used for disinfection and hand sterilization are often varied, with initial applications usually being above MICs. However, these concentrations are lowered by the process of dilution and/or by the duration of time spent hand washing. For example, in the process of hand washing, the concentration of the disinfectant is diluted by the amount of water used. However, the lack of correlation between biocide MICs and their lethal effects has been reported previously.^{25,29,30} By the use of the mean log reduction factor and percentage kill at the time tested for hand washing (30 seconds), the effectiveness of these agents was assessed for MSSA and MRSA and for hGISA and GISA (Table 4). The average duration of hand washing in a healthcare setting varied from 4.7 to 24 seconds, with the recommendation (by the Healthcare Infection Control Practices Advisory Committee) in the United States being 15 seconds. The data obtained allowed us to determine whether the intermediate vancomycin resistance phenotype, with its altered physiological features, had any affect on bacterial viability after hand washing (of less than 5-minute exposure).

By using this type of analysis, we showed that all Betadine products containing 4%–10% povidone-iodine had a higher log reduction factor for hGISA and GISA strains than for MSSA and MRSA strains, which suggests that the hGISA and GISA strains were more susceptible to these agents (Table 4). The chlorhexidine-containing agents, Hibisol and Hibiscrub,

were very effective against all strains at 30 seconds, irrespective of vancomycin susceptibility phenotype. Hibisol was slightly more effective, probably due to the additive effect of the isopropanol base. After 30 seconds of exposure to Aquasept (containing triclosan), and according to the EN 1040 standard criteria, the hGISA and GISA strains showed a lower log reduction factor than did the MSSA and MRSA strains (ie, 3.19 vs 3.95); therefore, Aquasept is less effective against the hGISA and GISA strains than against the MSSA and MRSA strains at 30 seconds (Figure). However, no difference was found between strains exposed to Manusept. This could be due to the additive effect of the isopropanol base, as seen for Hibisol, compared with Hibiscrub. When related hGISA and GISA strains were present, the efficacy of Aquasept, Manusept, and Sterillium were compared (Figure), and the data clearly show a reduction in susceptibility to these agents with increasing glycopeptide resistance. In the case of hexachlorophene, the hGISA and GISA strains were more susceptible than the MSSA and MRSA strains at 30 seconds, despite the agent being less effective against the former strain types after 600 seconds of exposure.

In summary, infection control to prevent the spread of MRSA infection in hospitals has focused on effective hand disinfection. Although most hand disinfectants remain active irrespective of the glycopeptide resistance phenotype, from the result of our study, it seems that GISA and hGISA strains are less susceptible to triclosan. On the other hand, Betadine agents were more effective against GISA and hGISA strains, especially after 30 seconds of exposure. Whether it is likely that the altered physiology of hGISA and GISA strains, compared with the vancomycin-susceptible MRSA and MSSA strains, accounts for the differences in the effectiveness of disinfection agents seen in our study is difficult to say. It is therefore important to investigate the exact genetic alterations taking place in these strains, so as to provide information for the purpose of combating disease and the spread of disease caused by these organisms that are resistant to certain cleaning agents.

ACKNOWLEDGMENTS

Financial support. Our study was partly funded by a research grant from the Hospital Infection Society, United Kingdom.

Potential conflicts of interest. All authors report no conflicts of interest relevant to this article.

Address reprint requests to Mandy Wootton, PhD, NPHS Microbiology Cardiff, University Hospital Wales, Heath Park, Cardiff CF14 4XW, UK (mandy.wootton@nphs.wales.nhs.uk).

REFERENCES

- Irizarry L, Merlin T, Rupp J, et al. Reduced susceptibility of methicillinresistant Staphylococcus aureus to cetylpyridinium chloride and chlorhexidine. Chemotherapy 1996; 42:248-252.
- 2. Kampf G, Jarosch R, Rüden H. Limited effectiveness of chlorhexidine

- based hand disinfectants against methicillin-resistant Staphylococcus aureus (MRSA). J Hosp Infect 1998; 38:297-303.
- 3. Al-Masaudi SB, Day MJ, Russell AD. Sensitivity of methicillin-resistant Staphylococcus aureus to some antibiotics, antiseptics and disinfectants. I Appl Bacteriol 1988; 65:329-337.
- 4. Akimitsu N, Hamamoto H, Inoue R, et al. Increase in resistance of methicillin-resistant Staphylococcus aureus to β-lactams caused by mutations conferring resistance to benzalkonium chloride, a disinfectant widely used in hospitals. Antimicrob Agents Chemother 1999; 43:3042-3043.
- 5. Smith K, Gemmell CG, Hunter IS. The association between biocide tolerance and the presence or absence of qac genes among hospitalacquired and community-acquired MRSA isolates. J Antimicrob Chemother 2008; 61:78-84.
- 6. Littlejohn TG, DiBeradino D, Messerotti LJ, Spiers SJ, Skurray RA. Structure and evolution of a family of genes encoding antiseptic and disinfectant resistance in Staphylococcus aureus. Gene 1991; 101:59-66.
- 7. Grinius L, Dreguniene G, Goldberg EB, et al. A staphylococcal multidrug resistance gene product is a member of a new protein family. Plasmid 1992; 27:119-129.
- 8. Noguchi N, Hase M, Kitta M, Sasatsu M, Deguchi K, Kono M. Antiseptic susceptibility and distribution of antiseptic-resistance genes in methicillin-resistant Staphylococcus aureus. FEMS Microbiol Lett 1999; 172:247-
- 9. Sidhu MS, Heir E, Leegaard T, et al. Frequency of disinfectant resistance genes and genetic linkage with β -lactamase transposon Tn552 among clinical staphylococci. Antimicrob Agents Chemother 2002; 46:2797-2803.
- 10. Weigel LM, Clewell DB, Gill SR, et al. Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus. Science 2003; 302: 1569-1571.
- 11. Berg T, Firth N, Apisiridej S, Hettiaratchi A, Leelaporn A, Skurray RA. Complete nucleotide sequence of pSK41: evolution of staphylococcal conjugative multiresistant plasmids. J Bacteriol 1998; 180:4350-4359.
- 12. Lyon BR, Skurray R. Antimicrobial resistance of Staphylococcus aureus: genetic basis. Microbiol Rev 1987; 51:88-134.
- 13. Paulsen IT, Gillespie MT, Littlejohn TG, et al. Characterisation of sin, a potential recombinase encoding gene of Staphylococcus aureus. Gene 1994; 141:109-114.
- 14. Brown MR, Gilbert P. Sensitivity of biofilms to antimicrobial agents. J Appl Bacteriol 1993; 74 Suppl:87S-97S.
- 15. Russell AD. Mechanisms of bacterial resistance to biocides. Int Biodeterior Biodegrad 1995; 36:247-265.

- 16. Gilbert P, Brown MR. Some perspectives on preservation and disinfection in the present day. Int Biodeterior Biodegrad 1995; 36:219-226.
- 17. Russell AD, Russell NJ. Biocides: activity, action and resistance. Symp Soc Gen Microb 1995; 53:327-365.
- CLSI. Performance standards for antimicrobial susceptibility testing. CLSI document. Wayne, PA: CLSI, 2003:M100-S13.
- 19. Council of Europe. Test methods for the antimicrobial activity of disinfectants in food hygiene. Strasbourg, France: Council of Europe, 1987.
- 20. British Standard EN 1040:1997. Chemical disinfectants and antiseptics. Basic bactericidal activity—test method and requirements (phase 1).
- 21. Suller MT, Russell AD. Antibiotic and biocide resistance in methicillinresistant Stathylococcus aureus and vancomycin-resistant Enterococcus. I Hosp Infect 1999; 43:281-291.
- Evans DJ, Allison DG, Brown M, et al. Growth rate and the resistance of gram-negative biofilms to cetrimide. J Antimicrob Chemother 1990; 26: 473-478.
- 23. Pfeltz RF, Singh VK, Schmidt JL, et al. Characterisation of passageselected vancomycin-resistant Staphylococcus aureus strains of diverse parental backgrounds. Antimicrob Agents Chemother 2000; 44:294-303.
- Sakoulas G, Eliopoulos GM, Moellering RC Jr, et al. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 2002; 46:1492-1502.
- 25. Cookson BD. Antiseptic resistance in methicillin-resistant Staphylococcus aureus: an emerging problem. In: Proceedings of the Seventh International Symposium. Stokholm, Sweden; 1994:227-234.
- 26. Bamber AI, Neal TI. An assessment of triclosan susceptibility in methicillin-resistant and methicillin-sensitive Staphylococcus aureus. J Hosp Infect 1999; 41:107-109.
- 27. Al-Doori Z, Morrison D, Edwards G, Gemmell C. Susceptibility of MRSA to triclosan. J Antimicrob Chemother 2003; 51:185-186.
- 28. Brenwald NP, Fraise AP. Triclosan resistance in methicillic-resistant Staphylococcus aureus (MRSA). J Hosp Infect 2003; 55:141-144.
- Cookson BD, Bolton MC, Platt JH. Chlorhexidine resistance in Staphvlococcus aureus or just an elevated MIC? An in vitro and in vivo assessment. Antimicrob Agents Chemother 1991; 35:1997-2002.
- 30. Farrelly HD, Stapleton P, Garvey RP, Price MR, Cookson BD. Transferable triclosan resistance in methicillin-resistant Staphylococcus aureus. In: "Clinical Microbiology New Perspectives," Joint Meeting of the Association of Medical Microbiology, British Society for Antimicrobial Chemotherapy, Hospital Infection Society and Irish Society of Clinical Microbiology. Dublin, Ireland; 1992. Abstract 41.